SECsense Logo

Keros Therapeutics, Inc. 8-K Report: Major Developments Unveiled on January 10, 2025

$KROS
Form 8-K
Filed on: 2025-01-10
Source
Keros Therapeutics, Inc. 8-K Report: Major Developments Unveiled on January 10, 2025

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Company Information:
  • Name: Keros Therapeutics, Inc.
  • CIK (Central Index Key): 0001664710
  • SEC Filing Type: 8-K (a report used to announce major events that shareholders should know about)
  • Company Structure: Incorporated in Delaware (DE)
  • IRS Employer Identification Number (EIN): 81-1173868
  • Address: 1050 Waltham Street, Suite 302, Lexington, MA 02421
  • Contact Number: 617-314-6297
  1. Stock Information:
  • Common Stock: $0.0001 par value per share
  • Ticker Symbol: KROS
  • Exchange: NASDAQ
  1. Filing Date:
  • Date of Filing: January 10, 2025
  1. Period of Reporting:
  • Start Date: January 10, 2025
  • End Date: January 10, 2025
  1. XBRL Information:
  • The report is formatted in XBRL (eXtensible Business Reporting Language), indicating it is structured for digital reporting and analysis.

Insights:

  • The report indicates a significant event or development for Keros Therapeutics on January 10, 2025, which may be important for investors and stakeholders to understand.
  • As an 8-K filing, this document is likely to contain critical information regarding changes in the company's operations, financial conditions, or other significant events that might affect its stock price or company outlook.
  • The presence of detailed identifiers (CIK, EIN) and standardized reporting formats (XBRL) suggests a commitment to transparency and regulatory compliance.
  • Investors may want to follow up on the specifics of the 8-K filing to assess its implications for Keros Therapeutics’ business and stock performance.